AIM To review Hepatitis C virus (HCV) prevalence and genotypes distribution worldwide.
METHODS We conducted a systematic study which represents one of the most …

The treatment of chronic hepatitis C virus (HCV) infection has the potential to change
significantly over the next few years as therapeutic regimens are rapidly evolving. However …

Background All-oral combination therapy is desirable for patients with chronic hepatitis C
virus (HCV) infection. We evaluated daclatasvir (an HCV NS5A replication complex inhibitor) …

Abstract Worldwide, an estimated 130–170 million people have HCV infection. HCV
prevalence is highest in Egypt at> 10% of the general population and China has the most …

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide. The long-term impact of HCV infection is highly variable, from minimal changes …

The present study was designed to determine the seroprevalence of hepatitis B and C virus
(HBV, HCV) infections and risk factors in the Turkish general population. Participants were …

Background Identifying gaps in care for people with chronic hepatitis C virus (HCV) infection
is important to clinicians, public health officials, and federal agencies. The objective of this …

The availability of the first molecular clone of the hepatitis C virus (HCV) genome allowed
the identification and biochemical characterization of two viral enzymes that are targets for …

Background An unmet need exists for interferon-free and ribavirin-free treatments for chronic
hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir …

Abstract An estimated 2%–3% of the world's population is living with hepatitis C virus (HCV)
infection, and each year,> 350 000 die of HCV-related conditions, including cirrhosis and …